Aurora Cannabis reports Q2-2026 revenue growth with stronger international sales but posts net loss and negative free cash flow. Learn why ACB stock is a hold.
Aurora Cannabis Inc. is rated a Buy with 40% upside in current levels and expects solid growth in medical cannabis sales.
Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.
Detailed price information for Aurora Cannabis Inc (ACB-Q) from The Globe and Mail including charting and trades.
This article first appeared on GuruFocus. Aurora Cannabis Inc (TSX:ACB) is set to release its Q2 2026 earnings on Nov 5, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback